Login to Your Account

Synta's Interim GALAXY Data Encouraging Despite Stock Fall

By Catherine Shaffer
Staff Writer

Friday, June 29, 2012
Positive interim results from its GALAXY trial of ganetespib and docetaxel for non-small-cell lung cancer (NSCLC) ran Synta Pharmaceuticals Corp.'s stock price off a cliff Thursday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription